John Erb

Non-Executive Chairman

John has served on the Osprey Medical board for 10 years. He is currently Chairman of the Board and Chief Executive Officer of CHF Solutions, Inc., a manufacturer of medical devices for the heart failure market. John previously served as Chairman of the Board for Vascular Solutions, Inc., manufacturer of medical devices for the cardiology and interventional radiology markets, which was acquired in 2017 by Teleflex, Inc. for US$1 billion. He has held numerous board positions, including CryoCath Technologies, Inc., acquired by Medtronic for US$350 million in 2008; and SenoRx, Inc., acquired by C.R. Bard for US$250 million in 2010. John has a bachelor’s degree in Business Administration from California State University, Fullerton.

Andy Jane

Non-Executive Director

Andy has more than 20 years of experience in the biomedical and IT industries. He is a Managing Director with Talu Ventures in Brisbane, Australia, with a portfolio of investments formerly managed by CM Capital Investments. Andy is a Board member of Piedmont Animal Health; Advent Pharmaceuticals Pty; Altiris Pharmaceuticals Inc.; and Piedmont Pharmaceuticals, Inc. He has a BSc Hons degree in Physics from the University of St Andrews in Scotland; a Master of Science degree in Instrumentation from the University of Manchester; a Diploma of Financial Services (Financial Markets) from AFMA; and a post-grad Certificate in Science Media & Journalism from the University of Technology in Sydney.

Sandra Lesenfants

Non-Executive Director

Sandra currently serves as the Vice President & General Manager of endoVenous business in the Medtronic Cardiac & Vascular Group. In her role, she is responsible for leading the development and global marketing of meaningful innovations and solutions to address chronic venous insufficiency, deep venous disease, and vascular embolization.

Sandra has broad commercial strategy experience and global business management skills from the vascular businesses at Medtronic, Covidien, EV3, and Siemens Healthcare. She has led several key integrations including the acquisition of Sapheon and its VenaSeal closure system, the integration of endoVenous business from Covidien’s Vascular Therapy business into Medtronic, and the integration of the embolization sales team from Medtronic’s Neurovascular division into endoVenous.

Sandra is on the Board of Directors of The American Venous Forum Foundation. She has a biomedical computer engineering degree from the University of Technology of Compiegne Engineering Institute in France.

Neville Mitchell

Non-Executive Director

Neville has served as a director with Osprey Medical since July 2012 and is Chairman of the Audit and Risk Committee. In 2017, Neville became a member of the Board of Directors of Sirtex Limited and the South Eastern Sydney Local Health District. Neville is also a member of the Board of Taxation (since 2015) and a panel member of the NSW Medical Device Fund. Neville was the Chief Financial Officer and Company Secretary of Cochlear Limited for over 20 years. He previously served as the President of Group 100 and a Director of the HEARing Cooperative Research Centre (CRC). Neville has a Bachelor of Commerce Degree and is a professional member of the Australian and South African Institutes of Chartered Accountants.

Chris Nave, Ph.D.

Non-Executive Director

Chris is a founding partner of Brandon Capital Partners and Chief Executive Officer of the Medical Research Commercialisation Fund.

Brandon Capital is a leading Australian life science investment firm with over $500M in assets currently under management.

Chris was previously Director of Commercialisation at the Baker IDI Heart and Diabetes Institute, Melbourne, Australia, where he led the commercialization of technologies developed at the Baker and Alfred Hospital. Chris was also Manager of the Biotechnology Team at Melbourne Ventures, the commercialisation company of the University of Melbourne.
In 2014, Chris was awarded the Australian Biotechnology Johnson & Johnson Industry Leadership Award, for his contribution to the industry.
Chris is currently a Director of Global Kinetics Corporation, PolyActiva, OccuRx Therapeutics, QueOncology and Athena Medicines. Chris has a first-class Honours degree in Science and a Ph.D. in Endocrinology and Physiology from the University of Melbourne and he has completed the Private Equity and Venture Capital Program at Harvard Business School, Boston, MA.